Daan Gene Co Ltd
SZSE:002030
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
D
|
Daan Gene Co Ltd
SZSE:002030
|
8.8B CNY |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.8B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
188B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
73.4B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.2B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Daan Gene Co Ltd
Glance View
Daan Gene Co., Ltd., a pioneer in China’s biotechnology scene, originated from the forward-thinking minds at Sun Yat-sen University. With its inception in 1993, the company swiftly positioned itself as a leader in the field of diagnostics, leveraging cutting-edge molecular biology technology. Comprising an initial team of scientific innovators, Daan Gene was poised to address the burgeoning need for rapid and accurate diagnostic solutions within the medical community. Their journey began with an unyielding focus on research and development, concentrating efforts on PCR (polymerase chain reaction) diagnostics. This core technology underpinning the company's offerings allowed Daan Gene to seamlessly transition research breakthroughs into practical, scalable diagnostic tools. Today, Daan Gene thrives by harnessing its advanced molecular diagnostic products, which serve hospitals, research institutions, and enterprises globally. The company's main revenue streams are driven by its expansive range of diagnostic kits and instruments, which address critical needs in infectious diseases, genetic testing, and oncology. With precision and efficiency at the heart of its operations, Daan Gene continually expands its product lineup, marketing its kits to healthcare providers who demand rapid and reliable diagnostic tools. This customer-centric approach enriches Daan Gene's reputation as a trusted partner in healthcare, fortifying its financial growth and staking its claims in the global diagnostics market.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Daan Gene Co Ltd is -97.2%, which is below its 3-year median of -44.3%.
Over the last 3 years, Daan Gene Co Ltd’s Operating Margin has decreased from 58.2% to -97.2%. During this period, it reached a low of -109.7% on Jun 30, 2025 and a high of 58.2% on Aug 30, 2022.